News Sentiment

JAZZ sentiment intelligence

Jazz Pharmaceuticals PLC news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 58 Balanced news tone 59 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 247.53 Week of 17 Jul 2026
Weighted tone 58/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

76/100 classification confidence.

Company focus 50

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend active

+1.5% over one week, +10.2% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

Jazz Pharmaceuticals stock hits all-time high at 250.85 USD

Market Reaction

Balanced read

66/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 76/100 classification
One-week reaction 1.5% Price digesting
Trend fit Trend active 10.2% over four weeks
Fair value 80.3% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 18
Neutral 38
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 50
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 11
Stock Titan 7
Quartr 7
simplywall.st 7
PR Newswire 6
Simply Wall Street 3
TradingView 3
Investing.com 2

Event Lens

What the news is about

Classified themes
Market update 26
Earnings 24
Analyst action 6
Balance sheet 1
Guidance 1
Regulatory and legal 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-59 of 59
Investing.com Canada Direct company coverage

Jazz Pharmaceuticals stock hits all-time high at 243.39 USD By Investing.com

Jazz Pharmaceuticals (JAZZ) stock has reached an all-time high of $243.46, trading just below its 52-week high, marking a 132% surge from its 52-week low. Despite this impressive performance, InvestingPro analysis suggests the stock remains undervalued, highlighting a strong gros

Tone
Positive 70/100
Event
Market update
Published
02 Jul 2026 19:40
Source
Investing.com Canada
Stock Titan Direct company coverage

Bruce Cozadd files Form 144 to sell shares — Jazz Pharmaceuticals (NASDAQ: JAZZ)

Jazz Pharmaceuticals (NASDAQ: JAZZ) director Bruce Cozadd has filed a Form 144 to sell shares, detailing recent dispositions of 6,000 shares on three separate dates in 2026 (April 1, May 1, and June 1). The filing also shows previously issued stock options from 2018 and 2019. Thi

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 20:11
Source
Stock Titan
Investing.com Canada Direct company coverage

Form 144 Jazz Pharmaceuticals Plc For: 1 July By Investing.com

This article announces the filing of Form 144 by Jazz Pharmaceuticals Plc for July 1. It is a brief financial news update from Investing.com. The content provided is primarily metadata and navigational information, indicating a simple notice of a regulatory filing.

Tone
Neutral 50/100
Event
Regulatory and legal
Published
01 Jul 2026 20:11
Source
Investing.com Canada
TradingView Direct company coverage

Price to earnings forward of Jazz Pharmaceuticals plc – NASDAQ:JAZZ

This article provides financial data for Jazz Pharmaceuticals plc (NASDAQ: JAZZ), focusing on its forward price-to-earnings ratio. It indicates that the market is closed and no trades were made, with the period value and changes left blank. The content

Tone
Neutral 50/100
Event
Earnings
Published
01 Jul 2026 14:39
Source
TradingView